BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Thursday. The brokerage issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reissued a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Price Performance

Shares of NASDAQ:BIOL opened at $0.01 on Thursday. The firm has a fifty day moving average price of $0.01 and a two-hundred day moving average price of $0.03. The company has a market cap of $317,366.50, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a one year low of $0.02 and a one year high of $1.94.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.